|Development of medicine for treating HIV infections||Over time, Shionogi and ViiV Healthcare have engaged in the joint research and development of dolutegravir, a new HIV integrase inhibitor. Developing countries account for more than 40% of the total global supply volume of the anti-HIV agent Tivicay® (dolutegravir), which is licensed to ViiV Healthcare, and its combinant drugs Triumeq® and Juluca®.
Starting in December 2012, ViiV Healthcare submitted New Drug Applications (NDAs) in the United States, Europe, Japan and other regions to have dolutegravir approved as a new drug. As of today, the drug has been made available for sale globally under the product name "Tivicay®. Registering dolutegravir in the Medicines Patent Pool has allowed generic manufacturers to manufacturer dolutegravir, either as a single-ingredient formulation or combined with other anti-HIV agents, and distribute it to more than 130 low-income and lower-middle-income countries since the patent is available free of charge.